{
  "subset": "indication",
  "disease": "Primary membranoproliferative glomerulonephritis",
  "relation": "indication",
  "gold_drugs": [
    "pegcetacoplan"
  ],
  "seeds_initial": [
    "Rituximab",
    "Corticosteroids",
    "Cyclosporine",
    "Mycophenolate mofetil",
    "Eculizumab",
    "Cyclophosphamide",
    "Tacrolimus",
    "Azathioprine",
    "Sirolimus",
    "Plasma exchange",
    "Bortezomib",
    "Belimumab"
  ],
  "seed_history": [
    [
      "Rituximab",
      "Corticosteroids",
      "Cyclosporine",
      "Mycophenolate mofetil",
      "Eculizumab",
      "Cyclophosphamide",
      "Tacrolimus",
      "Azathioprine",
      "Sirolimus",
      "Plasma exchange",
      "Bortezomib",
      "Belimumab"
    ]
  ],
  "final_report": {
    "final_recommendations": [
      {
        "hypothesis_id": "H1",
        "candidate": {
          "id": "drug_rituximab",
          "name": "Rituximab"
        },
        "score": 0.51,
        "graph_snapshot_ref": "GE_H1_round4",
        "key_assumptions": [
          "Rituximab能够影响病理过程",
          "感染风险的可能性需要进一步验证"
        ],
        "caveats": [
          "安全性尚存疑虑",
          "缺乏足够的替代机制支持"
        ],
        "confidence": "medium"
      },
      {
        "hypothesis_id": "H2",
        "candidate": {
          "id": "drug_corticosteroids",
          "name": "Corticosteroids"
        },
        "score": 0.48,
        "graph_snapshot_ref": "GE_H2_round4",
        "key_assumptions": [
          "类固醇在肾脏病中的广泛应用",
          "潜在感染风险需注意"
        ],
        "caveats": [
          "长期疗效尚不确定"
        ],
        "confidence": "medium"
      },
      {
        "hypothesis_id": "H3",
        "candidate": {
          "id": "drug_cyclosporine",
          "name": "Cyclosporine"
        },
        "score": 0.45,
        "graph_snapshot_ref": "GE_H3_round4",
        "key_assumptions": [
          "环孢素可用于相关患者",
          "感染风险存在"
        ],
        "caveats": [
          "缺乏大规模验证"
        ],
        "confidence": "medium"
      },
      {
        "hypothesis_id": "H4",
        "candidate": {
          "id": "drug_mycophenolate_mofetil",
          "name": "Mycophenolate mofetil"
        },
        "score": 0.43,
        "graph_snapshot_ref": "GE_H4_round4",
        "key_assumptions": [
          "作为免疫抑制剂能影响免疫反应",
          "可能存在安全风险"
        ],
        "caveats": [
          "缺乏临床数据支持"
        ],
        "confidence": "medium"
      },
      {
        "hypothesis_id": "H5",
        "candidate": {
          "id": "drug_eculizumab",
          "name": "Eculizumab"
        },
        "score": 0.41,
        "graph_snapshot_ref": "GE_H5_round4",
        "key_assumptions": [
          "针对补体系统可能有效",
          "感染风险需考虑"
        ],
        "caveats": [
          "疗效数据有限"
        ],
        "confidence": "medium"
      }
    ],
    "audit_report": {
      "decisive_graph_motifs": [
        {
          "pattern": "药物与疾病之间有直接支持关系",
          "reason": "现有药物与疾病的支持关系清晰"
        }
      ],
      "remaining_gaps": [
        "机制连通性不足，尚缺乏可替代机制的实证支持"
      ]
    },
    "heuristics": [],
    "prompt_patches": [],
    "seed_retrospective": {
      "batches": [],
      "lessons": []
    }
  },
  "experience_used": true,
  "explorer_prompt": "List drugs that could be indicated for the rare disease 'Primary membranoproliferative glomerulonephritis'. Return only names.\n\n# Prior guidance for Explorer:\n- 确保涵盖所有可能的作用机制，减少重复，提高覆盖范围\n\n# Heuristics:\n- When 肾脏疾病: then 优先考虑安全性与疗效的长期评估\n- When 免疫应答相关表型: then 对药物的免疫抑制效果进行详细分析"
}